ReviewEuropean archives of psychiatry and clinical neuroscience2012
Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias.
Review in European archives of psychiatry and clinical neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Systematic review of the diagnostic utility of SPECT imaging in dementia.European archives of psychiatry and clinical neuroscience · 2013Pooled it
- Sleep Disturbances Across Dementias and Cognitive Decline: Study Protocol for a Systematic Review and Network Meta-Analysis of Polysomnographic Findings.Journal of clinical medicine · 2025Article
- Description of the Method for Evaluating Digital Endpoints in Alzheimer Disease Study: Protocol for an Exploratory, Cross-sectional Study.JMIR research protocols · 2022Article
- Investigation of the Molecular Role of Brain-Derived Neurotrophic Factor in Alzheimer's Disease.Journal of molecular neuroscience : MN · 2022Review
- Biomarkers in Child Mental Health: a bio-psycho-social perspective is needed.Behavioral and brain functions : BBF · 2015Article
- Vagus somatosensory evoked potentials are delayed in Alzheimer's disease, but not in major depression.European archives of psychiatry and clinical neuroscience · 2014Article
- Diagnosis and management of the patient with suspected dementia in primary care.Drugs & aging · 2013Review
- Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease.European archives of psychiatry and clinical neuroscience · 2013Article
- Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations.International journal of cell biology · 2013Article
- Serum brain-derived neurotrophic factor levels in different neurological diseases.BioMed research international · 2013Article
- Selected issues of the DGPPN Congress in 2011.European archives of psychiatry and clinical neuroscience · 2012Article
- Are CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical Setting.Dementia and geriatric cognitive disorders extraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In light of the dramatically increasing prevalence of Alzheimer's disease (AD) to be expected in the future, the development of novel therapeutics, improved differential and early diagnostics, and means for the identification of individuals at risk are urgently needed. At present, instruments for a reliable differential diagnosis in clinical dementia, mild cognitive impairment, or prodromal stages have direct practical implications for differentiating secondary dementias from neurodegenerative conditions and for treatment decisions. It may also be reasonable to enforce the incorporation of biomarkers into clinical studies as surrogate outcome parameters and as an attempt to optimize recruitment criteria. Recently, revised research criteria increasingly rely on the interpretation of biomarker patterns, including neuroimaging and CSF-based neurochemical dementia diagnosis (NDD) in supporting the clinical diagnosis. Here, we review the performance of current core CSF biomarkers (Aβ(42) peptide, total tau protein and phosphorylated tau species) and try to define objectives for prospective markers, also considering blood-based tests, which would increase the acceptance and wide application of NDD. Moreover, we evaluate the role and the limitations of genotyping in the predictive diagnosis of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.